T-Cell-Based Universal Dengue Vaccine Design for Robust Protective Response.

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• Dengue virus poses a significant global health challenge, with current vaccines exhibiting limitations in efficacy and safety.
• Traditional antibody-based vaccines may offer insufficient protection and risk enhancing disease severity in naive individuals.

Purpose of the Study:

• To explore a new generation of T-cell epitope-based vaccines for dengue virus.
• To develop a safer and more broadly protective dengue vaccine candidate.

Main Methods:

• Focusing on conserved peptide regions within dengue virus non-structural proteins (NS3 and NS5) across all serotypes.
• Utilizing immunoinformatics to identify potent T-cell epitopes with high HLA binding affinity and cross-serotype conservation.
• Integrating selected epitopes into advanced delivery systems like mRNA and nanoparticles.

Main Results:

• Identified specific peptides (e.g., DTTPFGQQR, KPGTSGSPI, MYFHRRDLRL) that elicit strong cytotoxic and helper T-cell responses.
• Demonstrated potential for inducing viral clearance and long-term immune memory.
• Proposed delivery systems enhance antigen presentation and stability while mitigating risks of antibody-dependent enhancement.

Conclusions:

• T-cell epitope-based vaccines targeting conserved viral regions offer a promising strategy for dengue prevention.
• This approach aims to achieve balanced cellular and humoral immunity, similar to natural infection.
• The developed vaccine design represents a rational pathway toward a safer, cross-protective, and durable dengue vaccine.